Vol. 6 No. 4 (2026): April
Reimbursement Reviews

Olezarsen (Tryngolza)

decorative image of the issue cover

Published April 20, 2026

Key Messages

  • Reimbursement reviews are comprehensive assessments of the clinical effectiveness and cost-effectiveness, as well as patient and clinician perspectives, of a drug or drug class.
  • The assessments inform nonbinding recommendations that help guide the reimbursement decisions of Canada’s federal, provincial, and territorial governments, with the exception of Quebec.
  • This review assesses Olezarsen (Tryngolza), 80 mg per 0.8 mL solution in a single-dose autoinjector for subcutaneous use.
  • Indication: As an adjunct to diet in adult patients for the treatment of FCS.